Impact of Initial eGlycemic Management System Dosing Strategy on Time to Target Blood Glucose Range

Background: Glucommander (TM) (GM), an electronic glycemic management system, was implemented across a multi-hospital health system as the standard of care for glycemic control. GM provides insulin dosing recommendations based on patient-specific blood glucose (BG) trends after providers select either a custom dose or weight-based multiplier as the initial dosing strategy for the first 24hours. This study evaluated the impact of initial subcutaneous (SC) GM insulin dosing strategies on glycemic management. Methods: Non-intensive care unit patients treated with SC GM using either initial custom (based on provider discretion) or weight-based multiplier settings (0.3, 0.5, or 0.7units/kg/day) were evaluated in this retrospective chart review. The primary endpoint was time to target BG range defined as time to first two consecutive in range point of care BG. Secondary endpoints included percentage of BG values in target range, percentage of orders following institutional recommendations, length of stay (LOS), average BG, and incidence of hypoglycemia and hyperglycemia. Results: A review of 348 patients showed time to target BG was not significantly different between custom and multiplier groups (55 vs 64hours, P = .07). Target BG was achieved in less than half of patients in both groups (47% vs 44%, respectively). There were no differences in hospital LOS, proportion of BG in target range, rates of hypo/hyperglycemia, and average BG. Conclusions: Custom initial SC GM insulin dosing settings showed a nonsignificant decrease in time to target BG range compared to pre-defined multiplier settings. Future studies evaluating the impact of compliance with institutional recommendations on BG control are warranted.

Automated summary

This study evaluated the impact of different SC GM insulin dosing strategies on glycemic management and found that there was no significant difference in time to target BG between custom and multiplier groups, as well as in other outcomes.